Guest View
User: Pass: | become a member
Author Archive for Insider Scoop

UPDATE: Stifel Initiates Coverage On Deere & Company On Mixed Factors

Courtesy of Benzinga.

Related DE
Shares of Deere & Company Move On Revised USDA Production Figures
Top 4 NYSE Stocks In The Farm & Construction Machinery Industry With The Highest EPS
Some Firms Will Benefit from Falling Corn Prices (Fox Business)

In a report published Friday, Stifel analyst Robert Connors initiated coverage on Deere & Company (NYSE: DE) with a Hold rating.

In the report, Stifel noted, “DE stock is tied to the pricing power of farm commodities, and we believe the secular bull market is over. We believe it takes two years for crop prices to impact equipment sales, and we see a 28% drop in North American high horsepower farm equipment sales from the January 2014 peak. Pending a return to ethanol profitability, exports remain an opportunity for U.S. corn. But offsetting this, we see rising export competition from the Black Sea region.”

Deere & Company closed on Thursday at $86.33.

Latest Ratings for DE

Date Firm Action From To
Nov 2014 Stifel Nicolaus Initiates Coverage on Hold
Oct 2014 Citigroup Maintains Buy
Oct 2014 Bank of America Downgrades Neutral Underperform

View More Analyst Ratings for DE
View the Latest Analyst Ratings

Posted-In: Robert Connors StifelAnalyst Color Initiation Analyst Ratings





UPDATE: Compass Point Initiates Coverage On Western Union On Near-Term Catalysts, Ongoing Competitive Risk

Courtesy of Benzinga.

Related WU
Compass Point Initiates Western Union Company With Neutral
What's Driving the Business Services Sector? – Industry Outlook

In a report published Friday, Compass Point analyst Michael Tarkan initiated coverage on The Western Union Company (NYSE: WU) with a Neutral rating and $20.00 price target.

In the report, Compass Point noted, “We are assuming coverage of Western Union, Inc. (WU) with a Neutral rating and $20 price target. WU is the leading global money transfer and payment provider, with services offered in more than 200 countries. Western Union’s brand recognition, expansive network, and geographic diversification have provided insulation against industry-wide pricing pressure and a heightened regulatory environment; and management has remained the most active among peers in returning capital to shareholders through buybacks and dividends. However, the company is not immune to competitive headwinds and while we see some catalysts ahead, current valuation appears balanced, with shares trading at 11x our 2015 EPS estimate and 10x our 2016 estimate.”

Western Union closed on Thursday at $18.28.

Latest Ratings for WU

Date Firm Action From To
Nov 2014 Compass Point Initiates Coverage on Neutral
Nov 2014 Standpoint Research Downgrades Buy Hold
Nov 2014 Barclays Maintains Underweight

View More Analyst Ratings for WU
View the Latest Analyst Ratings

Posted-In: Compass Point Michael TarkanAnalyst Color Initiation Analyst Ratings





UPDATE: Compass Point Initiates Coverage On Xoom On Slowing Growth At An Unreasonable Price

Courtesy of Benzinga.

Related XOOM
Morning Market Losers
Benzinga's Top Downgrades

In a report published Friday, Compass Point analyst Michael Tarkan initiated coverage on Xoom Corporation (NASDAQ: XOOM) with a Sell rating and $11.00 price target.

In the report, Compass Point noted, “We are assuming coverage of Xoom Corporation (XOOM) with a Sell rating and $11 price target. Xoom is a leading international money transfer provider that focuses primarily on helping consumers send money from the U.S. to one of 31 different countries either directly online or through a mobile device. While we favor Xoom’s operating model relative to the legacy money transfer agent model, increasing competition and ongoing concentration risk create uncertainty—and with shares trading at 42x our 2015 EPS estimate and 27x our 2016 estimate, versus peers at 10x-11x and 9x-10x, respectively, valuation appears rich. Simply put, meaningful growth should continue over the next several years, but the stock still looks expensive relative to the potential risks, even though shares are already down 46% year-to-date.”

Xoom closed on Thursday at $14.80.

Latest Ratings for XOOM

Date Firm Action From To
Nov 2014 Compass Point Initiates Coverage on Sell
Oct 2014 Evercore Partners Downgrades Equal-weight Underweight
Jul 2014 First Analysis Initiates Coverage on Overweight

View More Analyst Ratings for XOOM
View the Latest Analyst Ratings

Posted-In: Compass Point Michael TarkanAnalyst Color Initiation Analyst Ratings





UPDATE: Morgan Stanley Reiterates On Splunk On Positive Outlook

Courtesy of Benzinga.

Related SPLK
Splunk Q3 Beats Views, Revenue Up 48%
Deutsche Bank Remains Positive On Splunk
Making Money With Charles Payne: 11/20/14 (Fox Business)

In a report published Friday, Morgan Stanley analyst Keith Weiss reiterated an Overweight rating on Splunk (NASDAQ: SPLK), and raised the price target from $66.00 to $82.00.

In the report, Morgan Stanley noted, “The combo of accelerating billings growth (+50% vs. 48% last Q) and improving profitability drives greater confidence in a durable FCF story developing for SPLK. The FY16 outlook is conservative but we see plenty of room for numbers to move higher and the stock to move towards our new $82 PT.”

Splunk closed on Thursday at $64.94.

Latest Ratings for SPLK

Date Firm Action From To
Nov 2014 Morgan Stanley Maintains Overweight
Nov 2014 Jefferies Initiates Coverage on Buy
Oct 2014 William Blair Upgrades Market Perform Outperform

View More Analyst Ratings for SPLK
View the Latest Analyst Ratings

Posted-In: Keith Weiss Morgan StanleyAnalyst Color Price Target Analyst Ratings





Jefferies: More Evidence Needed On SAP SE's HANA Acceptance

Courtesy of Benzinga.

Related SAP
Analysts: LinkedIn's Q4 Outlook 'Conservative'
Etihad Airways Selects SAP As A Strategic Technology Partner For Business Transformation

SAP SE's (NYSE: SAP) recently upgraded appliance that enables access to its service via mobile devices could be a growth driver, but evidence is so far sketchy, an analyst said Thursday.

Jefferies' John DiFucci launched coverage on the company with a Hold rating and $45.44 target. SAP's American depositary shares closed Thursday at $68.62 and are off more than 21 percent year-to-date.

SAP's high-performance analytic appliance, called HANA, is the company's "key enabler of success," DiFucci said.

Although the first versions of the product became available in 2010, DiFucci said it's "prudent to wait for more evidence" of apps for the appliance "before becoming constructive" on the stock.

Sap unveiled the HANA Enterprise Cloud service about 18 months ago and DiFucci said the product's ability to help companies take advantage of cloud computing could power growth for SAP.

Sap released an upgrade to HANA last month aimed at refining its data storage system and lowering costs.

Latest Ratings for SAP

Date Firm Action From To
Nov 2014 Jefferies Initiates Coverage on Hold
Oct 2014 Barclays Maintains Overweight
Oct 2014 FBR Capital Maintains Market Perform

View More Analyst Ratings for SAP
View the Latest Analyst Ratings

Posted-In: Jefferies John DiFucciAnalyst Color Price Target Initiation Analyst Ratings





Steve Miller Says Third Point Wanted Some 'Fresh Blood' On Dow Chemical's Board

Courtesy of Benzinga.

Related DOW
Dow Chemical Buries The Hatchet With Dan Loeb & Third Point
UPDATE: Deutsche Bank Reiterates On Dow Chemical Co Following Investor Meeting
Stocks Rally on China Rate Cut, Dovish Draghi (Fox Business)

The long drawn standoff between Dow Chemical Co (NYSE: DOW) and Dan Loeb’s Third Point LLC is finally seeing closure with the company agreeing to adding four new independent director to its Board as part of an agreement with the hedge fund.

Steve Miller, non-executive chairman at AIG, recently talked with Bloomberg’s Betty Liu regarding him joining Dow’s Board and how Dow Chemicals and Third Point reached a settlement.

"Well, I think ultimately both sides concluded that it was going to be far better to come to a consensual settlement rather than carrying on a proxy battle, which is both expensive and distracting to the company and so on and therefore the two sides were able to come to an agreement that includes four new directors," Miller said.

When queried about whether the settlement includes anything else, Miller replied that there are "other things to go along with it." According to Miller, "the main thing that Third Point wanted was to have some fresh blood come on the board with some new ideas for how to improve the return on assets of this very fine company and I am looking forward to that challenge.

"First order of business is going to be to become familiar with the assets of the company. It’s a very complex company, all over the globe; it's not public information as to exactly how they make their money. They are both upstream and downstream in their production of commodities and finished products," Miller added.

Miller highlighted that this settlement between Third Point and Dow Chemical includes a stand-still between the two entities, such that Loeb won’t be launching a proxy battle against the company.

Dow Chemical was recently trading at $52.45, up 1.9 percent.

Posted-In: Bloomberg Dan LoebCNBC News Hedge Funds Management Media General





UPDATE: Barrington Research Assumes Coverage On Haemonetics On Positive Revenue Outlook

Courtesy of Benzinga.

Related HAE
Events for the Week of Nov. 17-21, 2014
Midday Losers From November 3: RCS Capital, Haemonetics, Granite Construction And More

In a report published Thursday, Barrington Research analyst Michael Petusky assumed coverage on Haemonetics Corporation (NYSE: HAE) with an Outperform rating and $46.00 price target.

In the report, Barrington Research noted, “Our price target is $46 and we arrive at our target by attaching a 11x multiple to our 2016 adjusted EBITDA estimate of $245.0 million and a 10.3x multiple to our 2017 adjusted EBITDA estimate of $262.7.0 million. We feel a 10-12x multiple range is appropriate for companies like Haemonetics whose businesses contains elements of both a devices company, as well as a healthcare services business.”

Haemonetics closed on Wednesday at $36.41.

Latest Ratings for HAE

Date Firm Action From To
Nov 2014 Barrington Research Assumes Outperform
May 2014 Jefferies Maintains Buy
Apr 2014 Jefferies Maintains Buy

View More Analyst Ratings for HAE
View the Latest Analyst Ratings

Posted-In: Barrington Research Michael PetuskyAnalyst Color Initiation Analyst Ratings





UPDATE: Stifel Downgrades Sapient To Reflect Publicis Acquisition

Courtesy of Benzinga.

Related SAPE
Benzinga's Top Downgrades
Stifel Nicolaus Downgrades Sapient To Hold

In a report published Thursday, Stifel analyst David Grossman downgraded the rating on Sapient Corporation (NASDAQ: SAPE) from Buy to Hold, and removed the $19.50 price target.

In the report, Stifel noted, “We are downgrading SAPE to Hold to reflect the company’s acquisition by French advertising firm, Publicis, one of the large global ad agencies. We believe that is unlikely there will be a competing bid above this price, particularly given the substantial strategic premium (in our view). There is a $125mn break-up fee due from Sapient if the transaction is not approved (none to Publicis); however, we do not believe this is a likely scenario as 18% of the 50% shares required for approval have been committed by the two Sapient founders and the CEO.”

Sapient closed on Wednesday at $24.62.

Latest Ratings for SAPE

Date Firm Action From To
Nov 2014 Stifel Nicolaus Downgrades Buy Hold
Jul 2013 Raymond James Downgrades Outperform Market Perform
Feb 2013 Citigroup Downgrades Buy Neutral

View More Analyst Ratings for SAPE
View the Latest Analyst Ratings

Posted-In: David Grossman StifelAnalyst Color Downgrades Analyst Ratings





UPDATE: Morgan Stanley Reiterates On Mobileye NV On Operationally Flawless Quarter

Courtesy of Benzinga.

In a report published Thursday, Morgan Stanley analyst Ravi Shanker reiterated an Overweight rating on Mobileye NV (NYSE: MBLY), but removed the $50.00 price target.

In the report, Morgan Stanley noted, “As expected, 3Q was relatively uneventful, with a revenue driven op.beat offset by financing expenses. Behind the scenes, however, mgmt. reported that they had ‘successfully won programs…in several new models with new and existing OEM customers’. This is the only thing that matters at this stage.”

Mobileye NV closed on Wednesday at $46.75.

Latest Ratings for MBLY

Date Firm Action From To
Oct 2014 Barclays Maintains Overweight
Oct 2014 Raymond James Downgrades Outperform Market Perform
Sep 2014 Deutsche Bank Downgrades Buy Hold

View More Analyst Ratings for MBLY
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ravi ShankerAnalyst Color Price Target Analyst Ratings





UPDATE: Brean Capital Reiterates On Regeneron Pharmaceuticals On Increased Confidence

Courtesy of Benzinga.

Related REGN
US Stock Futures Mostly Flat Ahead Of Housing Data
Morning Market Losers
Making Money With Charles Payne: 10/31/14 (Fox Business)

In a report published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $390.00 to $450.00.

In the report, Brean Capital noted, “At the AHA meeting, positive results from six of the several ongoing ODYSSEY trials of alirocumab for hypercholesterolemia (LONG TERM, ALTERNATIVE, COMBO I, OPTIONS I, OPTIONS II, and HIGH FH) were presented. Alirocumab Q2W either alone (as in ALTERNATIVE) or in combination with statins significantly reduced the LDL-C level in several different patient types. Positive results from four other ODYSSEY trials (including the MONO trial) have already read out, and results from these ten ODYSSEY trials will form the basis for US and EU filings of alirocumab, which will be submitted by YE14. We anticipate US approval in mid-2015 with Priority Review status for the alirocumab filing. Four additional ODYSSEY trials (CHOICE I, CHOICE II, OLE, and OUTCOMES) will read out primary endpoints in 2015 and beyond. Given the strong efficacy on top of already substantial lipid lowering regimens, as well as a clean safety profile, we raise our target price to $450 from $390 because we project approval and rapid adoption for alirocumab as incrementally likely.”

Regeneron Pharmaceuticals closed on Wednesday at $415.25.

Latest Ratings for REGN

Date Firm Action From To
Nov 2014 Brean Capital Maintains Buy
Nov 2014 Argus Research Maintains Buy
Oct 2014 Guggenheim Securities Initiates Coverage on Buy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Brean Capital Jonathan AschoffAnalyst Color Price Target Analyst Ratings





 
 
 

Zero Hedge

LooTeRS!!!

Courtesy of ZeroHedge. View original post here.

Submitted by williambanzai7.

...

more from Tyler

Phil's Favorites

Bloomberg Sensationalism and Inaccuracies Regarding "Forced Nationalization of Crimea"

Courtesy of Mish.

A few days ago a friend emailed the Bloomberg article Russia Delivers a New Shock to Crimean Business: Forced Nationalization.

I replied something along the lines of "interesting, but I am going to bounce this of Jacob Dreizin", a US citizen who provides frequent updates to me regarding Ukraine.

I also bounced the article off Pater Tenebrarum at the Acting Man blog. Pater commented ...
Russian oligarchs stealing stuff back from Ukrainian oligarchs would be my guess. I should add, the arbitrariness of this process is of course quite disturbing (regardless of the fact that Ukraine's oligarchs are a bunch of corrupt thieves). But this strikes me mainly as a case of politically motivated payback. The oligarchs all aligned themselv...



more from Ilene

Chart School

The Big Four Economic Indicators: Real Retail Sales

Courtesy of Doug Short.

Note from dshort: With yesterday's release of the Consumer Price Index for October, I've updated Real Retail Sales for October.

Official recession calls are the responsibility of the NBER Business Cycle Dating Committee, which is understandably vague about the specific indicators on which they base their decisions. This committee statement is about as close as they get to identifying their method.

There is, however, a general belief that there are four big indicators that the committee weighs heavily in their cycle identification process. They are:

  • Industrial Production
  • Real Personal Income (excluding Transfer Payments)
  • Nonfarm Employment
  • Real Retail Sales
  • ...

    more from Chart School

    All About Trends

    Mid-Day Update

    Reminder: David is available to chat with Members, comments are found below each post.

    Click here for the full report.




    To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

    more from David

    Market Shadows

    EZCH - Not So EZ Year

    EZCH - Not So EZ Year

    By Ilene 

    After a disappointing quarter and some probable tax-selling, EZchip might be a good turnaround for next year.

    So I'm thinking we'll sell a stock or two out of Paul's otherwise neglected Virtual Portfolio (check back) and add EZCH.

    ...

    more from Paul

    OpTrader

    Swing trading portfolio - week of November 17th, 2014

    Reminder: OpTrader is available to chat with Members, comments are found below each post.

     

    This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

    We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

    Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

    To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



    more from OpTrader

    Sabrient

    Sector Detector: Investors make up new rules for their new market paradigm

    Reminder: Sabrient is available to chat with Members, comments are found below each post.

    Courtesy of Sabrient Systems and Gradient Analytics

    By Scott Martindale

    Investors in U.S. equities seem to have embraced a new market paradigm in which upside spikes come more swiftly than the downside selloffs. Remember when it used to be the other way around? When fear was stronger than greed? The market is consolidating its gains off the early-October V-bottom reversal, and no one seems to be in any hurry to unload shares this time around, with the holidays rapidly approaching and all. After all, there are bright blue skies directly overhead giving hope and respite from the early freeze blanketing the country.

    In this weekly update, I give my view of the current market environment, offer...



    more from Sabrient

    Stock World Weekly

    Stock World Weekly

    Newsletter writers are available to chat with Members regarding topics presented in SWW, comments are found below each post.

    The newest Stock World Weekly is ready. Click here for the this weekend's reading and sign in with your PSW user name and password. 

    Picture credit: AnnaER at Pixabay. 

    ...

    more from SWW

    Digital Currencies

    Ukraine Central Bank Bans Bitcoin "To Protect Citizens" From Financing Terrorism

    If you would have supposed that Ukraine had enough problems to make banning bitcoins a backburner issue, you'd have been wrong. The rationale, "to protect consumers' rights" makes little to no sense... The other one, "to keep money in the country" makes more sense. 

    Ukraine Central Bank Bans Bitcoin "To Protect Citizens" From Financing Terrorism

    Courtesy of ZeroHedge. View original post here.

    The Hryvnia has collapsed to new record lows near 15/USD this morning. The Central Bank and bankers "agreed to keep UAH at 15-16/USD" but are &qu...



    more from Bitcoin

    Option Review

    Yamana Gold call options sink

    Yamana Gold call options sink

    By Andrew Wilkinson at Interactive Brokers

    A four-year low for the spot price of gold has had a devastating impact on Yamana Gold (Ticker: AUY), with shares in the name down at the lowest price in six years. Some option traders were especially keen to sell premium and appear to see few signs of a lasting rebound within the next five months. The price of gold suffered again Wednesday as the dollar strengthened and stock prices advanced. The post price of gold fell to $1145 adding further pain to share prices of gold miners. Shares in Yamana Gold tumbled to $3.62 and the lowest price since 2008 as call option sellers used the April expiration contract to write premium at the $5.00 strike. That strike is now 38% above the price of the stock. Premium writers took in around 16-cents per contract o...



    more from Caitlin

    Pharmboy

    Biotechs & Bubbles

    Reminder: Pharmboy is available to chat with Members, comments are found below each post.

    Well PSW Subscribers....I am still here, barely.  From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.

    First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices.  Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment.  Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer.  For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...



    more from Pharmboy

    Help One Of Our Own PSW Members

    "Hello PSW Members –

    This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at jennifersurovy@yahoo.com with any questions.

    Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

    http://www.youcaring.com/medical-fundraiser/help-get-shadowfax-out-from-the-darkness-of-medical-bills-/126743

    Thank you for you time!




    FeedTheBull - Top Stock market and Finance Sites



    About Phil:

    Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

    Learn more About Phil >>


    As Seen On:




    About Ilene:

    Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

    Market Shadows >>